WUXI BIO Performance: Since January 20, WUXI BIO's share price has shown positive performance, surpassing its Chinese CRO peers and the healthcare sector, with a current price increase of 0.565%.

Market Insights: CLSA's research indicates that WUXI BIO's diversified shareholder structure provides resilience against geopolitical risks, and there is potential for growth acceleration before 2026, possibly exceeding expectations.

Investment Recommendations: Daiwa has rated WUXI BIO as a Buy, and the company is highlighted as a top pick in China's CRO/CDMO sector, with a target price of $48.5 and an Outperform rating.

Short Selling Data: As of January 22, 2026, WUXI BIO has experienced significant short selling, amounting to $189.95 million, with a short selling ratio of 13.739%.

Top Inflows: Guosen Securities reported the top ten Hong Kong stocks with the largest foreign capital inflows in 4Q25, led by INNOVENT BIO with an inflow of HKD6.43 billion.

Top Outflows: The report also highlighted the top ten stocks with the largest foreign capital outflows, with XIAOMI-W experiencing the highest outflow of HKD50.41 billion.

Short Selling Data: The report included short selling data for each stock, indicating significant short selling activity, particularly for XIAOMI-W and HSBC HOLDINGS.

Market Trends: The report reflects ongoing trends in the Hong Kong stock market, with notable shifts in foreign investment and short selling strategies among major companies.

Market Performance: The HSI fell by 39 points (0.1%) to 26,447, while the HSTI rose by 8 points (0.1%) to 5,691, and the HSCEI decreased by 24 points (0.3%) to 9,070.

Active Heavyweights: Notable movements included XIAOMI down 2.3%, BABA up 1.1%, and TENCENT down 0.2%, with significant short selling activity across these stocks.

HSI & HSCEI Constituents: ANTA SPORTS and LI NING saw significant declines of 5.8% and 4%, respectively, while BIDU-SW increased by 3.3%, reaching a new high.

HSMI & HSSI Constituents: SKYWORTH surged by 37.6% to a new high, with TCL ELECTRONICS and SF INTRA-CITY also showing strong gains of 17.1% and 15.5%, respectively.

Market Overview: The HSI fell 1% to 26,579, with the HSCEI down 0.9% and the HSTECH decreasing by 1.1%, resulting in a total half-day turnover of $132.94 billion.

AI Stocks Performance: XTALPI saw a gain of 3.4%, while KINGSOFT CLOUD, INSILICO, GDS-SW, and UNISOUND experienced declines ranging from 2.7% to 5.6%.

Power Equipment Stocks: DONGFANG ELEC and HARBIN ELECTRIC both rose significantly, with increases of 6.6% and 7.3%, respectively, despite the overall market trend.

Pharmaceutical Sector Decline: Several pharmaceutical stocks, including SINO BIOPHARM and 3SBIO, faced declines of 4.6% to 6.1%, with WUXI APPTEC also dropping by 2.8%.

Company Listing: Shanghai Duoning Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International as joint sponsors.

Clientele and Services: The company provides bioprocess solutions and laboratory products to pharmaceutical companies, CROs, CDMOs, and research institutions, with major clients including top biopharmaceutical firms in China.

Key Clients: WuXi Biologics is highlighted as one of the largest clients and suppliers, along with other notable shareholders such as CSPC Pharma, Akeso, and Keymed Bio-B.

Market Activity: The article notes short selling activity and stock performance for several companies in the sector, indicating market dynamics and investor interest.